Partnership will provide access to
standardized and optimized apheresis collection, cryopreservation
and bioprocessing processes throughout the U.S. and Europe
MINNEAPOLIS and NASHVILLE, Tenn. , Oct. 9, 2023
/PRNewswire/ -- Be The Match BioTherapies®, an
organization offering solutions for companies developing and
commercializing cell and gene therapies, and Cryoport (NASDAQ:
CYRX), a leading global provider of innovative products and
services to the fast-growing cell & gene therapy industry
enabling the future of medicine for a new era of life sciences,
today announced a new strategic partnership. The collaboration will
expand the capabilities of IntegriCell™, a standardized
bioprocessing, cryopreservation and distribution solution for the
global cell therapy market. With cryopreservation facilities
in the U.S. and EU, IntegriCell™ is poised to support decentralized and centralized manufacturing
models, enabling and accelerating patient access to innovative new
therapies.
Through this partnership, the companies will provide global
bioprocessing and cryopreservation support throughout the U.S. and
Europe. The integrated solution
combines Be The Match BioTherapies' world-class capabilities for
donor identification and collection of high-quality starting
material with Cryoport's cryopreservation, bioprocessing and
industry leading global logistics capabilities. The IntegriCell™
solution aims to deliver optimized cellular starting material by
providing cell processing, ideally within 24 hours post-collection,
using standardized bioprocessing and cryopreservation protocols
performed by experienced teams. This solution will provide cell and
gene therapy researchers, developers and manufacturers with
consistent starting materials cryopreserved to improve
manufacturing slot utilization leading to increased yields bringing
new cell and gene therapies to market faster and more
affordably.
"Cell and gene therapy developers have struggled to deliver
consistent starting materials with the cell yields that meet
their stringent standards — until now," said Mark Sawicki, President and CEO at Cryoport
Systems Inc. "Be The Match BioTherapies is a world-class partner
dedicated to advancing the cell and gene therapy eco-system, and
this collaboration presents a major opportunity to work together to
deliver best-in-class solutions to the cell and gene therapy
industry."
"We are excited to work with Cryoport to continue to set new
standards, expand accessibility and accelerate progress in the
development of potentially life-saving cell and gene therapies,"
said Chris McClain, Senior Vice
President Sales and Business Development at Be The Match
BioTherapies. "We believe IntegriCell represents a vital leap
forward in the cell therapy eco-system, one that will ultimately
lead to more consistent manufacturing yields and better clinical
outcomes."
About Be The Match BioTherapies
Be The Match
BioTherapies is the only cell and gene therapy solutions provider
with customizable services to support the end-to-end cell therapy
supply chain. Backed by the industry-leading experience of the
National Marrow Donor Program®/Be The Match®
and a research partnership with the CIBMTR® (Center for
International Blood and Marrow Transplant Research®),
the organization designs solutions that advance the development of
cell and gene therapies across the globe.
Be The Match BioTherapies is dedicated to accelerating patient
access to life-saving cell and gene therapies by providing
high-quality cellular source material from the Be The Match
Registry®, the world's most diverse registry of more
than 7 million potential blood stem cell donors. Through
established relationships with apheresis, marrow collection, and
transplant centers worldwide, the organization develops, onboards,
trains, and manages expansive collection networks to advance cell
therapies. Be The Match BioTherapies uses a proven infrastructure
consisting of regulatory compliance and managed logistics experts
and cell therapy supply chain case managers to successfully
transport and deliver regulatory-compliant life-saving therapies
across the globe. Through the CIBMTR, Be The Match extends services
beyond the cell therapy supply chain to include long-term follow-up
tracking for FDA-approved CAR-T therapies.
For more information,
visit www.BeTheMatchBioTherapies.com or follow Be The
Match BioTherapies on LinkedIn or Twitter.
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is
a leading global provider of innovative products and services to
the fast-growing Cell & Gene Therapy industry - enabling the
future of medicine for a new era of life sciences. With 48
strategic locations across 17 countries, covering the Americas,
EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Cryoport's global platform
provides mission-critical bio-logistics, bio-storage,
bio-processing, cryopreservation, and cryogenic systems to the life
sciences markets worldwide.
For more information, visit www.cryoport.com or follow @cryoport
on Twitter at www.twitter.com/cryoport for live updates.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/be-the-match-biotherapies-and-cryoport-partner-to-accelerate-the-development-of-cell-and-gene-therapies-301950105.html
SOURCE Cryoport, Inc.